Gregory S. Brigham
Research Subjects
Research Interests
Gregory S. Brigham has a total of 241 co-authors. Here are the top co-authors by number of shared publications:
- Theresa Winhusen
Department of Psychiatry and Behavioral Neuroscience University of Cincinnati College of Medicine Cincinnati OH USA
18 shared publications - Dennis M. Donovan
Alcohol and Drug Abuse Institute, University of Washington
7 shared publications - Edward V. Nunes
Department of Psychiatry Columbia University Irving Medical Center New York NY USA
6 shared publications Eugene Somoza
Addiction Sciences Division, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH 45220, USA; Cincinnati VA Medical Center, Cincinnati, OH 45220, USA
6 shared publicationsFrankie Kropp
Addiction Sciences Division, Department of Psychiatry and Behavioral Neuroscience, University of Cincinnati College of Medicine, Cincinnati, OH 45229, USA
6 shared publicationsRobert Lindblad
The EMMES Corporation, 401 N. Washington St., Rockville, MD 20850, United States
6 shared publications
Latest Publications
- 30 December 2015
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 42 (1) , 88-97
Decision-making processes as predictors of relapse and subsequent use in stimulant-dependent patients
Background: Decision-making processes have been posited to affect treatment outcome in addicted patients. Objective: The present multi-site study assessed whether two measures of decision-making predicted relapse and subsequent use in stimulant-dependent patients. Methods: A total of 160 methamphetamine- or cocaine-dependent patients participating in a multi-site clinical trial evaluating a modified 12-step facilitation intervention for stimulant-dependent patients (STAGE-12) were assessed. Decision-making processes of risk and delay (Iowa Gambling Task [IGT]) and response reversal (Wisconsin Card Sorting Task [WCST]) were obtained shortly after treatment admission followed by assessment of stimulant use over the next six months. The relationships of the IGT and WCST (Perseverative Errors) with relapse (yes/no) and days of stimulant use during the 6-month period following post-randomization were evaluated. Results: Performance on the IGT and WCST did not significantly predict relapse status or time to relapse. Unexpectedly, worse performance on the IGT was associated with a fewer number of stimulant use days (p = 0.001). In contrast, worse performance on the WCST (more perseverative errors) was associated with a greater number of stimulant use days (p = 0.0003). The predictive effects of perseverative errors on subsequent use were confined to methamphetamine-dependent and Minority participants. Conclusions: Decision-making processes, as measured in the current study, do not uniformly predict relapse or subsequent use. A decrease in the salience attribution of non-drug reinforcers may explain the positive relationship between IGT performance and post-relapse use. More comprehensive and global measures of impulsiveness may better assess relapse risk and use.
- 30 December 2015
- Published by Taylor & Francis in The American Journal of Drug and Alcohol Abuse
- Vol. 42 (1) , 88-97
Decision-making processes as predictors of relapse and subsequent use in stimulant-dependent patients
Background: Decision-making processes have been posited to affect treatment outcome in addicted patients. Objective: The present multi-site study assessed whether two measures of decision-making predicted relapse and subsequent use in stimulant-dependent patients. Methods: A total of 160 methamphetamine- or cocaine-dependent patients participating in a multi-site clinical trial evaluating a modified 12-step facilitation intervention for stimulant-dependent patients (STAGE-12) were assessed. Decision-making processes of risk and delay (Iowa Gambling Task [IGT]) and response reversal (Wisconsin Card Sorting Task [WCST]) were obtained shortly after treatment admission followed by assessment of stimulant use over the next six months. The relationships of the IGT and WCST (Perseverative Errors) with relapse (yes/no) and days of stimulant use during the 6-month period following post-randomization were evaluated. Results: Performance on the IGT and WCST did not significantly predict relapse status or time to relapse. Unexpectedly, worse performance on the IGT was associated with a fewer number of stimulant use days (p = 0.001). In contrast, worse performance on the WCST (more perseverative errors) was associated with a greater number of stimulant use days (p = 0.0003). The predictive effects of perseverative errors on subsequent use were confined to methamphetamine-dependent and Minority participants. Conclusions: Decision-making processes, as measured in the current study, do not uniformly predict relapse or subsequent use. A decrease in the salience attribution of non-drug reinforcers may explain the positive relationship between IGT performance and post-relapse use. More comprehensive and global measures of impulsiveness may better assess relapse risk and use.
- 25 May 2015
- Published by Wiley in The American Journal on Addictions
- Vol. 24 (5) , 403-409
“Sub is a weird drug:” A web‐based study of lay attitudes about use of buprenorphine to self‐treat opioid withdrawal symptoms
Background: Illicit use of buprenorphine has increased in the U.S., but our understanding of its use remains limited. This study aims to explore Web‐forum discussions about the use of buprenorphine to self‐treat opioid withdrawal symptoms.Methods: PREDOSE, a novel Semantic Web platform, was used to extract relevant posts from a Web‐forum that allows free discussions on illicit drugs. First, we extract information about the total number of buprenorphine‐related posts per year between 2005 and 2013. Second, PREDOSE was used to identify all posts that potentially contained discussions about buprenorphine and opioid withdrawal. A total number of 1,217 posts that contained these terms were extracted and entered into NVivo data base. A random sample of 404 (33%) posts was selected and content analyzed.Results: Buprenorphine‐related posts increased over time, peaking in 2011. The posts were about equally divided between those that expressed positive and negative views about the effectiveness of buprenorphine in relieving withdrawal symptoms. Web‐forum participants emphasized that buprenorphine's effectiveness may become compromised because of the “size of a person habit,” and/or when users repeatedly switch back and forth between buprenorphine and other illicit opioids. Most posts reported use of significantly lower amounts of buprenorphine (≤2 mg) than doses used in standard treatment. Concomitant use of other psychoactive substances was also commonly reported, which may present significant health risks.Conclusions: Our findings highlight the usefulness of Web‐based data in drug abuse research and add new information about lay beliefs about buprenorphine that may help inform prevention and policy measures. (Am J Addict 2015;24:403 –409)
- 25 May 2015
- Published by Wiley in The American Journal on Addictions
- Vol. 24 (5) , 403-409
“Sub is a weird drug:” A web‐based study of lay attitudes about use of buprenorphine to self‐treat opioid withdrawal symptoms
Background: Illicit use of buprenorphine has increased in the U.S., but our understanding of its use remains limited. This study aims to explore Web‐forum discussions about the use of buprenorphine to self‐treat opioid withdrawal symptoms.Methods: PREDOSE, a novel Semantic Web platform, was used to extract relevant posts from a Web‐forum that allows free discussions on illicit drugs. First, we extract information about the total number of buprenorphine‐related posts per year between 2005 and 2013. Second, PREDOSE was used to identify all posts that potentially contained discussions about buprenorphine and opioid withdrawal. A total number of 1,217 posts that contained these terms were extracted and entered into NVivo data base. A random sample of 404 (33%) posts was selected and content analyzed.Results: Buprenorphine‐related posts increased over time, peaking in 2011. The posts were about equally divided between those that expressed positive and negative views about the effectiveness of buprenorphine in relieving withdrawal symptoms. Web‐forum participants emphasized that buprenorphine's effectiveness may become compromised because of the “size of a person habit,” and/or when users repeatedly switch back and forth between buprenorphine and other illicit opioids. Most posts reported use of significantly lower amounts of buprenorphine (≤2 mg) than doses used in standard treatment. Concomitant use of other psychoactive substances was also commonly reported, which may present significant health risks.Conclusions: Our findings highlight the usefulness of Web‐based data in drug abuse research and add new information about lay beliefs about buprenorphine that may help inform prevention and policy measures. (Am J Addict 2015;24:403 –409)
- 1 November 2014
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 39 (2) , 211-223
Achieving Cannabis Cessation — Evaluating N-acetylcysteine Treatment (ACCENT): Design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network
- 1 November 2014
- Published by Elsevier in Contemporary Clinical Trials
- Vol. 39 (2) , 211-223
Achieving Cannabis Cessation — Evaluating N-acetylcysteine Treatment (ACCENT): Design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network
- 1 October 2014
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 47 (4) , 265-274
Is level of exposure to a 12-step facilitation therapy associated with treatment outcome?
- 1 October 2014
- Published by Elsevier in Journal of Substance Abuse Treatment
- Vol. 47 (4) , 265-274
Is level of exposure to a 12-step facilitation therapy associated with treatment outcome?
- 1 July 2014
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 140, e125
Cocaine Use Reduction with Buprenorphine (CURB): Study methods and participant characteristics
- 1 July 2014
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 140, e125
Cocaine Use Reduction with Buprenorphine (CURB): Study methods and participant characteristics
- 27 May 2014
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 75 (07) , 757-764
Multisite, Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Trial to Evaluate the Efficacy of Buspirone as a Relapse-Prevention Treatment for Cocaine Dependence
To evaluate the potential efficacy of buspirone as a relapse-prevention treatment for cocaine dependence. A randomized, double-blind, placebo-controlled, 16-week pilot trial was conducted at 6 clinical sites between August 2012 and June 2013. Adult crack cocaine users meeting DSM-IV-TR criteria for current cocaine dependence who were scheduled to be in inpatient/residential substance use disorder (SUD) treatment for 12-19 days when randomized and planning to enroll in local outpatient treatment through the end of the active treatment phase were randomized to buspirone titrated to 60 mg/d (n = 35) or placebo (n = 27). All participants received psychosocial treatment as usually provided by the SUD treatment programs in which they were enrolled. Outcome measures included maximum days of continuous cocaine abstinence (primary), proportion of cocaine use days, and days to first cocaine use during the outpatient treatment phase (study weeks 4-15) as assessed by self-report and urine drug screens. There were no significant treatment effects on maximum continuous days of cocaine abstinence or days to first cocaine use. In the female participants (n = 23), there was a significant treatment-by-time interaction effect (χ²₁ = 15.26, P < .0001), reflecting an increase in cocaine use by those receiving buspirone, relative to placebo, early in the outpatient treatment phase. A similar effect was not detected in the male participants (n = 39; χ²₁ = 0.14, P = .70). The results suggest that buspirone is unlikely to have a beneficial effect on preventing relapse to cocaine use and that buspirone for cocaine-dependent women may worsen their cocaine use outcomes. ClinicalTrials.gov identifier: NCT01641159.
- 27 May 2014
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 75 (07) , 757-764
Multisite, Randomized, Double-Blind, Placebo-Controlled Pilot Clinical Trial to Evaluate the Efficacy of Buspirone as a Relapse-Prevention Treatment for Cocaine Dependence
To evaluate the potential efficacy of buspirone as a relapse-prevention treatment for cocaine dependence. A randomized, double-blind, placebo-controlled, 16-week pilot trial was conducted at 6 clinical sites between August 2012 and June 2013. Adult crack cocaine users meeting DSM-IV-TR criteria for current cocaine dependence who were scheduled to be in inpatient/residential substance use disorder (SUD) treatment for 12-19 days when randomized and planning to enroll in local outpatient treatment through the end of the active treatment phase were randomized to buspirone titrated to 60 mg/d (n = 35) or placebo (n = 27). All participants received psychosocial treatment as usually provided by the SUD treatment programs in which they were enrolled. Outcome measures included maximum days of continuous cocaine abstinence (primary), proportion of cocaine use days, and days to first cocaine use during the outpatient treatment phase (study weeks 4-15) as assessed by self-report and urine drug screens. There were no significant treatment effects on maximum continuous days of cocaine abstinence or days to first cocaine use. In the female participants (n = 23), there was a significant treatment-by-time interaction effect (χ²₁ = 15.26, P < .0001), reflecting an increase in cocaine use by those receiving buspirone, relative to placebo, early in the outpatient treatment phase. A similar effect was not detected in the male participants (n = 39; χ²₁ = 0.14, P = .70). The results suggest that buspirone is unlikely to have a beneficial effect on preventing relapse to cocaine use and that buspirone for cocaine-dependent women may worsen their cocaine use outcomes. ClinicalTrials.gov identifier: NCT01641159.
- 1 May 2014
- Published by Elsevier in Addictive Behaviors
- Vol. 39 (5) , 897-900
Parenting under the influence: The effects of opioids, alcohol and cocaine on mother–child interaction
- 1 May 2014
- Published by Elsevier in Addictive Behaviors
- Vol. 39 (5) , 897-900
Parenting under the influence: The effects of opioids, alcohol and cocaine on mother–child interaction
- 10 December 2013
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 75 (04) , 336-343
A Randomized Trial of Concurrent Smoking-Cessation and Substance Use Disorder Treatment in Stimulant-Dependent Smokers
From The Journal of Clinical Psychiatry:
- 10 December 2013
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 75 (04) , 336-343
A Randomized Trial of Concurrent Smoking-Cessation and Substance Use Disorder Treatment in Stimulant-Dependent Smokers
From The Journal of Clinical Psychiatry: